Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry

Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry

There are 224 different pipeline products in clinical development for hematological malignancies. Twenty-three (10%) of these drugs are in late-phase studies and are forecast to achieve peak sales of $3.5 billion in 2018. Drug developers are keen to replicate the success of the two blockbusters: Biogen Idec/Genentech/Roche's Rituxan (rituximab) and Novartis's Gleevec (imatinib).

Epidemiology of the hematological malignancies split by disease subtype, covering the seven major markets as well as the top 5 rest of world markets

Overview of the current treatment options for leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes with identification of unmet needs

Examination of the late-phase hematological malignancies pipeline, key company market strategies and opportunities for drug developers

Pipeline insight based on qualitative interviews with key opinion leaders in the field of hematological malignancies

There are 13 molecular-targeted therapies, six immunotherapeutic agents and four cytotoxic agents in late-phase clinical development for hematological malignancies. Immunotherapeutic agents are forecast to achieve the highest class sales of $1.7 billion in the seven major markets by 2018.

Pipeline agents holding the greatest commercial potential include the immunoconjugated monoclonal antibodies Arzerra (ofatumumab; Genmab/GlaxoSmithKline), galiximab (Biogen Idec) and lumiliximab (Biogen Idec), as well as the cytotoxic agent pixantrone (Novartis).

Smaller, niche indications are increasingly attracting R&D interest as a result of the high unmet needs that persist in a number of hematological malignancy subtypes. At least 9 (39%) of the 23 late-phase pipeline agents are targeting patient sub-populations to potentially fill gaps in the market and facilitate launch.

Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipeline

Identify the key products in late-phase development based on sales forecasts to 2018 and Datamonitor's drug assessment methodology

Assess how the future treatment of many hematological malignancies will incorporate pipeline products

Publication: 39904
Library Code: DMHC2507
Type: Report
Format: PDF & SlidePack & DataPack
Pages: 373

Table of Contents
Price: $11,400.00 / €7,619.76

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions